July 23, 2019 Nuplazid’s schizophrenia flop provides Advance warning Acadia has tried to see the positives after a pivotal trial failure with Nuplazid in schizophrenia, but the data bode ill for other label-expansion studies.
May 03, 2019 Upcoming events – Acadia hopes for new indications for Nuplazid Knockout interim data from Acadia’s trials of its antipsychotic in schizophrenia and dementia could make for early approval. But the chances of this are not high.
October 14, 2016 Upcoming events – Acadia data in Alzheimer's and La Jolla's acute blood pressure project
